Physician profile
Daniel V Patel
NPI 1669683769
$227,219.68
in general payments reported to CMS, 2019-2025
14 companies · $44K in 2025
The $44K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $39K · 2021: $11K · 2022: $31K · 2023: $21K · 2024: $36K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $86K · Travel and Lodging: $8,402 · Honoraria: $4,000 · Food and Beverage: $2,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $86,160.00 |
| Travel and Lodging | $8,402.42 |
| Honoraria | $4,000.00 |
| Food and Beverage | $2,987.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $179,410.61 | 2019-2025 | Gore Viabahn Endoprosthesis With Heparin, Viabahn Endoprosthesis With Propaten Bioactive Surface, Gore Viabahn Endoprosthesis |
| Philips North America LLC | $30,868.61 | 2019-2025 | Igt Devices Undivided |
| Medtronic Vascular, INC. | $7,500.83 | 2019-2020 | |
| Merit Medical Systems INC | $7,386.19 | 2022-2025 | Wrapsody Stent Graft |
| Medtronic, INC. | $637.32 | 2021-2025 | Ellipsys Vascular Access System, In.Pact Admiral |
| Bard Peripheral Vascular, INC. | $544.75 | 2023-2024 | Pristine |
| Astrazeneca Pharmaceuticals LP | $219.99 | 2019-2021 | |
| Covidien LP | $130.91 | 2020 | |
| Inari Medical, INC. | $117.27 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cook Medical LLC | $113.22 | 2022-2024 | Cook |
| Mallinckrodt Hospital Products INC. | $102.70 | 2023 | Terlivaz |
| Regeneron Pharmaceuticals, INC. | $99.75 | 2024 | Dupixent |
| Veloxis Pharmaceuticals, INC. | $53.93 | 2019 | |
| Cormedix INC. | $33.60 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.